Drug
Emapalumab Lzsg Gamifant
Emapalumab Lzsg Gamifant: highest development phase Post-Market, developed by Swedish Orphan Biovitrum. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Swedish Orphan Biovitrum
Trials
| Drug | Phase | Indication |
|---|---|---|
| Emapalumab-Lzsg 5 MG/ML [Gamifant] NCT05744063 | Post-Market | Primary Hemophagocytic Lymphohistiocytosis |
Latest
No recent events.
Follow Emapalumab Lzsg Gamifant on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.